Latest
The moving edge of the record
Outcomes just published, the agenda for the next meeting, and recommended drugs still waiting for a PBS listing. All from pbs.gov.au, updated as the source documents appear.
Just decided
From the PBAC's short post-meeting outcomes summary. The full Public Summary Documents follow ~6–8 weeks later; items move into the record as each PSD lands.
| Drug | Indication | Outcome |
|---|---|---|
| AdalimumabAmgevita® | Crohn disease, ulcerative colitis, active juvenile idiopathic arthritis, complex refractor… | Recommended |
| AdalimumabYuflyma® | Moderate to severe ulcerative colitis, severe juvenile idiopathic arthritis, severe chroni… | Recommended |
| Adrenaline (Epinephrine)Neffy® | Acute severe allergic reactions in children and adults at significant risk of anaphylaxis | Recommended |
| AlectinibAlecensa® | Non-small cell lung cancer (NSCLC) anaplastic lymphoma kinase (ALK)-positive | Noted |
| AmivantamabRybrevant® | Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutat… | Recommended |
| Asciminib | Chronic myeloid leukaemia (CML) in chronic phase, newly diagnosed | Withdrawn |
| AsciminibScemblix® | Chronic myeloid leukaemia (CML) | Recommended |
| Avacincaptad PegolIzervay® | Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) | Recommended |
| BurosumabCrysvita® | Tumour induced osteomalacia (TIO) with hypophosphataemia | Recommended |
| CanakinumabIlaris® | Colchicine-resistant Familial Mediterranean Fever (crFMF) in children aged 2 years and old… | Recommended |
| CannabidiolEpidyolex® | Severe myoclonic epilepsy in infancy (Dravet syndrome) | Recommended |
| CiclosporinVevye® | Dry eye disease with keratitis | Recommended |
| DupilumabDupixent® | Uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation | Recommended |
| DurvalumabImfinzi® | Gastric cancer (GC) or gastro-oesophageal junction cancer (GOJC) | Recommended |
| EdaravoneRadicava® | Amyotrophic lateral sclerosis (ALS) | Recommended |
| Efgartigimod AlfaVyvgart® | Generalised myasthenia gravis (gMG) with anti-acetylcholine receptor (AChR) antibody posit… | Recommended |
| Efgartigimod AlfaVyvgart® | Chronic inflammatory demyelinating polyneuropathy (CIDP) | Not recommended |
| EnoxaparinClexane® Safety-Lock, Clexane® Forte Safety-Lock | Prevention and treatment of thromboembolic disorders, haemodialysis | Withdrawn |
| EnzalutamideXtandi® | Non-metastatic hormone sensitive prostate cancer (nmHSPC) with biochemical recurrence at h… | Recommended |
| Glycomacropeptide Formula With Docosahexaenoic Acid And Low PhenylalaninePKU GMPro® Delight | Phenylketonuria (PKU) | Recommended |
| IncobotulinumtoxinaXeomin® | Moderate to severe spasticity of the lower limb in adults following stroke, traumatic brai… | Recommended |
| Inotuzumab OzogamicinBesponsa® | Acute lymphoblastic leukaemia (ALL) | Noted |
| LanreotideLACREO | Acromegaly, functional carcinoid tumour, non-functional gastroenteropancreatic neuroendocr… | Recommended |
| Loncastuximab TesirineZynlonta® | Diffuse large B-cell lymphoma (DLBCL) relapsed or refractory | Not recommended |
| MepolizumabNucala® | Chronic obstructive pulmonary disease (COPD) with eosinophilic phenotype | Recommended |
| Multicomponent Meningococcal Group B VaccineBexsero® | Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis group … | Noted |
| NemolizumabNemluvio® | Atopic dermatitis, moderate to severe | Recommended |
| NivolumabOpdivo® | Malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), squamo… | Recommended |
| ObinutuzumabGazyva® | Lupus nephritis, active class III or IV | Recommended |
| OmalizumabOmlyclo® | Uncontrolled severe asthma, severe chronic spontaneous urticaria | Recommended |
| OdevixibatBylvay® | Alagille syndrome (ALGS), cholestatic pruritus | Not recommended |
| PegcetacoplanEmpaveli® | Complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerul… | Not recommended |
| PegvaliasePalynziq® | Phenylketonuria (PKU) | Deferred |
| Respiratory Syncytial Virus VaccineArexvy® | Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) | Recommended |
| RetifanlimabZynyz® | Squamous cell anal carcinoma (SCAC), locally recurrent or metastatic, not previously treat… | Recommended |
| RetifanlimabZynyz® | Merkel cell carcinoma (MCC), metastatic or recurrent | Recommended |
| RiluzoleTeglutik® | Amyotrophic lateral sclerosis (ALS) | Noted |
| RisperidoneUzedy® | Schizophrenia | Recommended |
| RomidepsinROMIDEPSIN-REACH | Peripheral T-cell lymphoma relapsed or refractory | Recommended |
| RuxolitinibJakavi® | Myelofibrosis, graft versus host disease, polycythemia vera | Recommended |
| Sars-Cov-2 MrnaSpikevax® | Prevention of coronavirus disease 2019 (COVID-19) | Not Applicable |
| SelpercatinibRetevmo® | Medullary thyroid cancer (MTC), locally advanced or metastatic, with RET gene variant | Recommended |
| TacrolimusaZematop® | Atopic dermatitis | Recommended |
| TafamidisVyndamax® | Transthyretin amyloid cardiomyopathy (ATTR-CM) | Not recommended |
| TafasitamabMinjuvi® | Follicular lymphoma (FL), relapsed or refractory | Recommended |
| TarlatamabImdelltra® | Extensive-stage small cell lung cancer (ES-SCLC) | Not recommended |
| TeclistamabTecvayli® | Relapsed or refractory multiple myeloma (RRMM) | Recommended |
| TildrakizumabIlumya® | Severe chronic plaque psoriasis | Recommended |
| TirzepatideMounjaro®, Mounjaro® KwikPen® | Type 2 diabetes mellitus (T2DM) inadequately controlled | Recommended |
| TofersenQalsody® | Amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) gene mutation | Recommended |
| Trastuzumab DeruxtecanEnhertu® | Breast cancer, hormone receptor positive (HR-positive) HER2-low or HER2-ultralow metastati… | Not recommended |
| UpadacitinibRinvoq® | Fistulising Crohn's disease (FCD) | Recommended |
| UstekinumabArdelya® | Severe chronic plaque psoriasis, severe psoriatic arthritis | Recommended |
| VorasidenibVoranigo® | Astrocytoma or oligodendroglioma, isocitrate dehydrogenase-mutant | Recommended |
| Adalimumab, Etrasimod, Golimumab, Infliximab, Ozanimod, Tofacitinib, Upadacitinib, Ustekinumab, VedolizumabVarious | Inflammatory bowel disease (severe Crohn disease, moderate to severe Crohn disease, severe… | Recommended |
| Adalimumab, InfliximabHumira®, Amgevita®, Hadlima®, Hyrimoz®, Yuflyma®, Abrilada®, Inflectra®, Ixifi®, Remicade®, Remsima®, Renflexis® | Crohn disease and ulcerative colitis in paediatric patients | Noted |
| Erythropoietin Stimulating Agents, Iron Chelating Agents, Bulevirtide | Various | Noted |
| Preservative-Free Ocular Lubricants | Severe dry eye disease | Noted |
| Designated Registered Nurse Prescribing Medicines | Various | Noted |
Coming up
| Drug | Indication | Purpose |
|---|---|---|
| AcalabrutinibCalquence® | Mantle cell lymphoma | Consider revised proposal for listing acalabrutinib in combination with bendamus… |
| AmivantamabRybrevant SC® | Non-small cell lung cancer | Request listing of subcutaneous form of amivantamab for first-line (with chemoth… |
| Apadamtase Alfa / Cinaxadamtase AlfaAdzynma® | Congenital thrombotic thrombocytopenic purpura | Request listing of enzyme replacement therapy for prevention of acute events in … |
| Belantamab MafodotinBlenrep® | Relapsed and/or refractory multiple myeloma | Resubmission to request listing in combination with bortezomib and dexamethasone… |
| Bempedoic AcidNexletol® | Hypercholesterolaemia | Request listing as monotherapy and with ezetimibe for hypercholesterolaemia in s… |
| Bempedoic Acid With EzetimibeNexlizet® | Hypercholesterolaemia | Request listing for hypercholesterolaemia in statin-intolerant patients or on ma… |
| Birch TriterpenesFilsuvez® | Dystrophic or junctional epidermolysis bullosa | Request listing for treatment of partial thickness skin wounds in patients aged … |
| Brentuximab VedotinAdcetris® | Hodgkin lymphoma | Request listing in combination with multi-drug chemotherapy for first-line treat… |
| Budesonide With Glycopyrronium And FormoterolBreztri Aerosphere® | Severe asthma | Request listing of new form for maintenance treatment of severe asthma in adults… |
| DepemokimabExdensur® | Uncontrolled severe eosinophilic asthma | Request listing for uncontrolled severe eosinophilic asthma in patients aged 12+… |
| DonidalorsenZirdawny® | Hereditary angioedema | Request listing for long-term prophylaxis of recurrent attacks in patients with … |
| ElacestrantOrserdu® | Breast cancer | Resubmission for ER+/HER2- locally advanced or metastatic breast cancer with ESR… |
| FinerenoneKerendia® | Heart failure | Request listing for symptomatic heart failure (NYHA Class II-IV) with LVEF great… |
| GuselkumabTremfya® | Severe Crohn disease | Consider revised proposal for listing guselkumab in severe CD with failed respon… |
| Loncastuximab TesirineZynlonta® | Diffuse large B-cell lymphoma | Resubmission for relapsed or refractory DLBCL in patients with two or more prior… |
| Mifepristone And MisoprostolMS-2 Step® | Termination of an intra-uterine pregnancy | Request change to allow use for intra-uterine pregnancy up to 70 days of gestati… |
Awaiting listing
A positive PBAC recommendation is not a listing — pricing and listing arrangements come after. These drugs have a “yes” but no PBS subsidy yet; the wait is counted from the meeting date.
| Drug | Indication | PBAC meeting | Waiting |
|---|---|---|---|
| TildrakizumabIlumya® | Severe chronic plaque psoriasis | Mar 2026 | 114 days |
| UstekinumabArdelya® | Severe chronic plaque psoriasis Severe psoriatic arthritis | Mar 2026 | 114 days |
| Avacincaptad PegolIzervay® | Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) | Mar 2026 | 114 days |
| CanakinumabIlaris® | Colchicine-resistant or intolerant Familial Mediterranean Fever (crFMF) | Mar 2026 | 114 days |
| DupilumabDupixent® | Chronic obstructive pulmonary disease (COPD) | Mar 2026 | 114 days |
| LanreotideLacreo | Acromegaly Functional carcinoid tumour Non-functional gastroenteropancreatic neuroendocrin… | Mar 2026 | 114 days |
| Glycomacropeptide Formula With Docosahexaenoic Acid And Low PhenylalaninePKU GMPro® Delight | Phenylketonuria (PKU) | Mar 2026 | 114 days |
| DurvalumabImfinzi® | Gastric cancer (GC) or gastro-oesophageal junction cancer (GOJC) | Mar 2026 | 114 days |
| AdalimumabYuflyma® | Moderate to severe ulcerative colitis Severe juvenile idiopathic arthritis Severe … | Mar 2026 | 114 days |
| AsciminibScemblix® | Chronic myeloid leukaemia (CML) | Mar 2026 | 114 days |
| Efgartigimod AlfaVyvgart® | Generalised myasthenia gravis (gMG) | Mar 2026 | 114 days |
| ObinutuzumabGazyva® | Lupus nephritis | Mar 2026 | 114 days |
| UpadacitinibRinvoq® | Fistulising Crohn’s disease (FCD) | Mar 2026 | 114 days |
| RisperidoneUzedy® | Schizophrenia | Mar 2026 | 114 days |
| TeclistamabTecvayli® | Relapsed or refractory multiple myeloma (RRMM) | Mar 2026 | 114 days |
| SelpercatinibRetevmo® | Medullary thyroid cancer (MTC) | Mar 2026 | 114 days |
| NemolizumabNemluvio® | Atopic dermatitis | Mar 2026 | 114 days |
| MepolizumabNucala® | Chronic obstructive pulmonary disease (COPD) | Mar 2026 | 114 days |
| EnzalutamideXtandi® | Non-metastatic hormone sensitive prostate cancer (nmHSPC) | Mar 2026 | 114 days |
| RomidepsinRomidepsin-Reach | Relapsed or refractory peripheral T-cell lymphoma | Mar 2026 | 114 days |
| AmivantamabRybrevant® | Non-small cell lung cancer (NSCLC) | Mar 2026 | 114 days |
| AdalimumabAmgevita® | Crohn disease Ulcerative colitis Active juvenile idiopathic arthritis Complex refractory … | Mar 2026 | 114 days |
| RuxolitinibJakavi® | Myelofibrosis Graft versus host disease Polycythemia vera | Mar 2026 | 114 days |
| CannabidiolEpidyolex® | Severe myoclonic epilepsy in infancy (Dravet syndrome) | Mar 2026 | 114 days |
| IncobotulinumtoxinaXeomin® | Moderate to severe spasticity of the lower limb in adults following an acute event | Mar 2026 | 114 days |
| OmalizumabOmlyclo® | Uncontrolled severe asthma Uncontrolled severe allergic asthma Severe chronic spontaneous … | Mar 2026 | 114 days |
| NivolumabOpdivo® | Malignant melanoma Non-Small Cell Lung Cancer (NSCLC) Renal Cell Carcinoma (RCC) Squamous … | Mar 2026 | 114 days |
| CiclosporinVevye® | Dry eye disease with keratitis | Mar 2026 | 114 days |
| BurosumabCrysvita ® | Tumour induced osteomalacia (TIO) | Mar 2026 | 114 days |
| Adrenaline (Epinephrine)Neffy® | Acute allergic reaction with anaphylaxis | Mar 2026 | 114 days |
| VorasidenibVoranigo® | Astrocytoma or oligodendroglioma | Mar 2026 | 114 days |
| TofersenQalsody® | Amyotrophic lateral sclerosis (ALS) | Mar 2026 | 114 days |
| TirzepatideMounjaro® Mounjaro® KwikPen® | Type 2 diabetes mellitus | Mar 2026 | 114 days |
| RetifanlimabZynyz® | Merkel cell carcinoma (MCC) | Mar 2026 | 114 days |
| TacrolimusaZematop® | Atopic dermatitis | Mar 2026 | 114 days |
| RetifanlimabZynyz® | Squamous cell anal carcinoma (SCAC) | Mar 2026 | 114 days |
| TafasitamabMinjuvi® | Relapsed and/or refractory follicular lymphoma (FL) | Mar 2026 | 114 days |
| PembrolizumabKeytruda | Advanced and metastatic cancers | Dec 2025 | 205 days |
| Velmanase AlfaHEQUINEL | Alpha-mannosidosis | Dec 2025 | 205 days |
| SeladelparLivdelzi® | Primary biliary cholangitis (PBC) | Dec 2025 | 205 days |
| BlinatumomabBlincyto | Acute lymphoblastic leukaemia (ALL) Precursor B-cell acute lymphoblastic leukaemia … | Dec 2025 | 205 days |
| FenfluramineFintepla® | Lennox-Gastaut Syndrome (LGS) | Nov 2025 | 240 days |
| Encorafenib BinimetinibBraftovi® Mektovi® | Non-small cell lung cancer (NSCLC) | Nov 2025 | 240 days |
| Onasemnogene AbeparvovecZolgensma® | Spinal muscular atrophy (SMA) | Nov 2025 | 240 days |
| CetrorelixFemvi® | Assisted Reproductive Technology (ART) | Nov 2025 | 240 days |
| Efgartigimod AlfaVyvgart® | Generalised myasthenia gravis (gMG) | Nov 2025 | 240 days |
| OmaveloxoloneSkyclarys® | Friedreich’s ataxia | Nov 2025 | 240 days |
| TucatinibTukysa® | Breast cancer | Nov 2025 | 240 days |
| ZanubrutinibBrukinsa® | Mantle cell lymphoma (MCL) Waldenstrom macroglobulinaemia (WM) Chronic lymphocytic … | Nov 2025 | 240 days |
| AfliberceptEydenzelt® | Subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM) | Nov 2025 | 240 days |
| SemaglutideWegovy® | Established cardiovascular disease (eCVD) with obesity | Nov 2025 | 240 days |
| Estradiol With ProgesteroneBijuva® | Vasomotor symptoms in post menopausal women | Nov 2025 | 240 days |
| FezolinetantVeoza® | Moderate to severe menopause-related vasomotor symptoms (VMS) | Nov 2025 | 240 days |
| AcalabrutinibCalquence® | Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) | Nov 2025 | 240 days |
| TocilizumabAvtozma® | Severe active juvenile idiopathic arthritis Severe active rheumatoid arthritis Systemic … | Nov 2025 | 240 days |
| DelgocitinibAnzupgo® | Chronic hand eczema (CHE) | Nov 2025 | 240 days |
| PegcetacoplanSyfovre® | Bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD) | Nov 2025 | 240 days |
| TezepelumabTezspire® | Asthma | Nov 2025 | 240 days |
| Mirvetuximab SoravtansineElahere® | Epithelial ovarian, fallopian tube or primary peritoneal cancer | Nov 2025 | 240 days |
| NitisinoneOrfadin® | Hereditary tyrosinaemia Type 1 (HT-1) | Nov 2025 | 240 days |
| OsimertinibTagrisso® | Non-small cell lung cancer (NSCLC) | Sep 2025 | 301 days |
| ZolbetuximabVyloy® | Gastric or gastroesophageal junction (G/GOJ) cancer | Sep 2025 | 301 days |
| LeniolisibJoenja® | Activated PI3K delta syndrome (APDS) | Jul 2025 | 359 days |
| AcalabrutinibCalquence® | Mantle cell lymphoma | Jul 2025 | 359 days |
| MethadoneMethadone-AFT | Chronic severe disabling pain | Jul 2025 | 359 days |
| OsimertinibTagrisso® | Unresectable locally advanced (Stage III) non-small cell lung cancer | Jul 2025 | 359 days |
| AbaloparatideEladynos® | Osteoporosis | Jul 2025 | 359 days |
| Pegunigalsidase AlfaElfabrio® | Fabry disease | Jul 2025 | 359 days |
| Insulin DegludecTresiba® Penfill® | Type 1 diabetes mellitus | Jul 2025 | 359 days |
| GuselkumabTremfya® | Severe Crohn disease | Jul 2025 | 359 days |
| PaliperidonePaljuna Monthly | Schizophrenia | Jul 2025 | 359 days |
| TacrolimusaZematop® | Atopic dermatitis | Jul 2025 | 359 days |
| BulevirtideHepcludex® | Chronic hepatitis D | Jul 2025 | 359 days |
| Triglycerides, Medium ChainMCT Oil | Chylous ascites Chylothorax Fat malabsorption Hyperlipoproteinaemia type 1 Intractable chi… | Jul 2025 | 359 days |
| Triglycerides - Medium Chain, FormulaMonogen® | Dietary management of conditions requiring a source of medium chain triglycerides Hyperlip… | Jul 2025 | 359 days |
| GuselkumabTremfya® | Chronic plaque psoriasis (CPP) | May 2025 | 420 days |
| OmalizumabXolair® | Chronic rhinosinusitis with nasal polyps (CRSwNP) | May 2025 | 420 days |
| AlectinibAlecensa® | Non-small cell lung cancer (NSCLC) | May 2025 | 420 days |
| TeprotumumabTepezza® | Thyroid Eye Disease (TED) | May 2025 | 420 days |
| NatalizumabTyruko® | Relapsing-remitting multiple sclerosis (RRMS) | Mar 2025 | 478 days |
| UstekinumabEpyztek® | Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex … | Mar 2025 | 478 days |
| MidostaurinRydapt® | Advanced systemic mastocytosis | Mar 2025 | 478 days |
| PertuzumabPerjeta® | Human epidermal growth factor receptor 2-positive (HER2+) locally advanced, inflammatory … | Mar 2025 | 478 days |
| MogamulizumabPoteligeo® | Cutaneous T-cell lymphoma (CTCL) | Mar 2025 | 478 days |
| Efgartigimod AlfaVyvgart® | Generalised myasthenia gravis (gMG) | Mar 2025 | 478 days |
| Polatuzumab VedotinPolivy® | Diffuse large B-cell lymphoma (DLBCL) | Mar 2025 | 478 days |
| GemcitabineGemcitabine Sandoz® | Various cancers | Mar 2025 | 478 days |
| RozanolixizumabRystiggo® | Generalised myasthenia gravis (gMG) | Mar 2025 | 478 days |
| ToripalimabZytorvi® | Nasopharyngeal carcinoma | Mar 2025 | 478 days |
| AbrocitinibCibinqo® | Severe atopic dermatitis | Nov 2024 | 604 days |
| LanadelumabTakhzyro® | Hereditary angioedema (HAE) | Nov 2024 | 604 days |
| LeuprorelinEligard® | Central precocious puberty Locally advanced (stage C) or metastatic (stage D) carcinoma … | Nov 2024 | 604 days |
| OlaparibLynparza® | Metastatic castration-resistant prostate cancer (mCRPC) | Nov 2024 | 604 days |
| ErenumabAimovig® | Chronic migraine | Nov 2024 | 604 days |
| Enfortumab VedotinPadcev® | Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer (la/mUC) | Nov 2024 | 604 days |
| BudesonideBudenofalk® | Ulcerative colitis | Nov 2024 | 604 days |
| RivaroxabanXarelto® | Prevention of venous thromboembolism Chronic stable atherosclerotic disease | Nov 2024 | 604 days |
| Triglycerides, Long Chain With Glucose PolymerProZero® | Proven inborn errors of protein metabolism | Nov 2024 | 604 days |
| ProgesteroneUtrogestan® | Luteal phase support | Jul 2024 | 723 days |
| Milk Powder -- SyntheticLocasol® | Hypercalcaemia | Jul 2024 | 723 days |
| ApalutamideErlyand® | Non-metastatic castration-resistant carcinoma of the prostate Metastatic castration-sensit… | Jul 2024 | 723 days |
| Adrenaline (Epinephrine)Jext® Jnr; Jext® | Acute allergic reaction with anaphylaxis | Jul 2024 | 723 days |
| Drospirenone With EthinylestradiolYaz®; Yasmin® | Oral contraceptive Moderate acne vulgaris in women who seek oral contraception Premenstrua… | Jul 2024 | 723 days |
| Levodopa With Carbidopa And EntacaponeLecigon® | Advanced Parkinson disease | Jul 2024 | 723 days |
| Amino Acid Formula With Vitamins, Minerals And Long Chain Polyunsaturated Fatty Acids Without PhenylalaninePKU Start | Phenylketonuria | Mar 2024 | 842 days |
| LebrikizumabEbglyss® | Atopic dermatitis | Mar 2024 | 842 days |
| Sodium Zirconium CyclosilicateLokelma® | Chronic hyperkalaemia | Mar 2024 | 842 days |
| TofacitinibXeljanz® XR | Rheumatoid arthritis Psoriatic arthritis | Mar 2024 | 842 days |
| Amino Acid Formula Supplemented With Prebiotics, Probiotics And Long Chain Polyunsaturated Fatty AcidsNeocate® Syneo | Cows' milk protein enteropathy Severe cows' milk protein enteropathy with failure … | Mar 2024 | 842 days |
| CabozantinibCabometyx® | Advanced clear cell variant renal cell carcinoma in combination with nivolumab | Mar 2024 | 842 days |
| UstekinumabWezlana | Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis | Mar 2024 | 842 days |
| UstekinumabStelara® | Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis Fistulising … | Mar 2024 | 842 days |
| PembrolizumabKeytruda® | Squamous cell carcinoma (SCC) | Nov 2023 | 975 days |
| LenacapavirSunlenca® | Human immunodeficiency virus (HIV) | Nov 2023 | 975 days |
| CabotegravirApretude® | Pre-exposure prophylaxis of HIV infection | Sep 2023 | 1036 days |
| SomapacitanSogroya® | Paediatric growth hormone deficiency (GHD) | Jul 2023 | 1094 days |
| MirikizumabOmvoh® | Moderate to severe ulcerative colitis (MUSC) | Jul 2023 | 1094 days |
| MobocertinibExkivity® | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Jul 2023 | 1094 days |
| Relatlimab And NivolumabOpdualag® | Melanoma | Jul 2023 | 1094 days |
| Trastuzumab DeruxtecanEnhertu® | Jul 2023 | 1094 days | |
| Carmellose With Glycerol And Hyaluronic AcidOptive Fusion® | Severe dry eye syndrome | May 2023 | 1155 days |
| Hyaluronic Acid With Polyethylene Glycol 400 With Propylene Glycol With Hydroxypropyl GuarSystane® Hydration | Severe dry eye syndrome | May 2023 | 1155 days |
| AlirocumabPraluent® | Familial heterozygous hypercholesterolaemia and non-familial hypercholesterolaemia. | Mar 2023 | 1213 days |
| BudesonideJorveza® | Eosinophilic oesophagitis | Mar 2023 | 1213 days |
| Glycomacropeptide And Essential Amino Acids With Vitamins And MineralsTylactin RTD | Tyrosinaemia | Mar 2023 | 1213 days |
| RomosozumabEvenity® | Osteoporosis | Mar 2023 | 1213 days |
| AbemaciclibVerzenio™ | Breast cancer | Mar 2023 | 1213 days |
| Amino Acid Synthetic Formula Supplemented With Long Chain Polyunsaturated Fatty AcidsEleCare® LCP | Cows' milk protein enteropathy; Severe cows' milk protein enteropathy with failure … | Mar 2023 | 1213 days |
| High Fat Formula With Vitamins, Minerals And Trace Elements And Low In Protein And CarbohydrateKetoVie 3:1 KetoVie 4:1 KetoVie Peptide 4:1 | Ketogenic diet | Mar 2023 | 1213 days |
| InfliximabRemsima® SC | Rheumatoid arthritis | Nov 2022 | 1339 days |
| Amino Acid Formula With Vitamins And Minerals Without PhenylalaninePKU Squeezie® | Phenylketonuria | Nov 2022 | 1339 days |
| Budesonide With Glycopyrronium And FormoterolBreztri Aerosphere® DFP-EvoCap | Chronic obstructive pulmonary disease | Nov 2022 | 1339 days |
| Elexacaftor With Tezacaftor And With Ivacaftor, And IvacaftorTrikafta® | Cystic fibrosis | Nov 2022 | 1339 days |
| MidazolamZyamis® | Epilepsy | Nov 2022 | 1339 days |
| RisankizumabSkyrizi® | Crohn Disease | Nov 2022 | 1339 days |
| UstekinumabStelara® | Severe Crohn disease Severe chronic plaque psoriasis | Jul 2022 | 1458 days |
| ProgesteroneCyclogest® | Infertility | Jul 2022 | 1458 days |
| Human Menopausal GonadotrophinMenopur® 600 Menopur® 1200 | Assisted Reproductive Technology | Jul 2022 | 1458 days |
| TrientineCuprior® | Wilson disease | May 2022 | 1519 days |
| DulaglutideTrulicity® | Type 2 diabetes mellitus | May 2022 | 1519 days |
| PembrolizumabKeytruda® | Gastro-oesophageal cancers | May 2022 | 1519 days |
| FremanezumabAjovy® | Chronic migraine | Mar 2022 | 1577 days |
| SomapacitanSogroya® | Adult growth hormone deficiency | Mar 2022 | 1577 days |
| Beclometasone With FormoterolFostair® | Chronic obstructive pulmonary disease | Mar 2022 | 1577 days |
| BimekizumabBimzelx® | Plaque psoriasis | Mar 2022 | 1577 days |
| RabeprazolePariet® | Complex gastro-oesophageal reflux disease; Scleroderma oesophagus; Gastro-oesophageal … | Mar 2022 | 1577 days |
| OzanimodZeposia® | Ulcerative colitis | Mar 2022 | 1577 days |
| DupilumabDupixent® | Atopic dermatitis | Mar 2022 | 1577 days |
| GalcanezumabEmgality® | Migraine | Mar 2022 | 1577 days |
| SecukinumabCosentyx® | Paediatric psoriasis | Nov 2021 | 1703 days |
| AdalimumabHulio® | Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile … | Nov 2021 | 1703 days |
| EtanerceptRymti® | Rheumatoid arthritis; Plaque psoriasis; Ankylosing spondylitis; Psoriatic arthritis; … | Nov 2021 | 1703 days |
| Insulin AspartTruvelog®; Truvelog® Solostar | Diabetes mellitus | Nov 2021 | 1703 days |
| RisankizumabSkyrizi® | Severe chronic plaque psoriasis | Nov 2021 | 1703 days |
| IxekizumabTaltz® | Non radiographic axial spondyloarthritis (nr-axSpA) | Nov 2021 | 1703 days |
| MelatoninSlenyto® | Insomnia | Nov 2021 | 1703 days |
| Amino Acid Formula With Vitamins And Minerals Without PhenylalaninePKU express 15® | Phenylketonuria | Jul 2021 | 1822 days |
| HydrocortisoneAlkindi® | Adrenal Insufficiency | Jul 2021 | 1822 days |
| Amino Acid Formula With Vitamins And Minerals Without MethionineHCU express 15® | Pyridoxine non-responsive homocystinuria | Jul 2021 | 1822 days |
| Amino Acid Formula With Vitamins And Minerals Without Phenylalanine And TyrosineTYR express 15® | Tyrosinaemia | Jul 2021 | 1822 days |
| Amino Acid Formula With Vitamins And Minerals Without PhenylalaninePKU express 20® | Phenylketonuria | Jul 2021 | 1822 days |
| Amino Acid Formula With Vitamins And Minerals Without Valine, Leucine And IsoleucineMSUD express 15® | Maple syrup urine disease | Jul 2021 | 1822 days |
| BortezomibDBL Bortezomib® | Multiple Myeloma | Jul 2021 | 1822 days |
| NivolumabOpdivo® | Second-line squamous cell oesophageal carcinoma (2L OSCC) | Jul 2021 | 1822 days |
| EvolocumabRepatha® | Familial heterozygous hypercholesterolaemia; Non-familial hypercholesterolaemia; Familial … | Mar 2021 | 1941 days |
| High Fat Formula With Vitamins, Minerals And Trace Elements And Low In Protein And CarbohydrateKetoCal 3:1® KetoCal 4:1® | Ketogenic Diet | Mar 2021 | 1941 days |
| AvelumabBavencio® | Urothelial carcinoma | Mar 2021 | 1941 days |
| AvelumabBavencio® | Renal cell carcinoma (RCC) | Mar 2021 | 1941 days |
| BevacizumabMvasi® | Metastatic colorectal cancer Epithelial ovarian, fallopian tube, or primary peritoneal … | Nov 2020 | 2067 days |
| TofacitinibXeljanz® | Chronic plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative arthritis | Nov 2020 | 2067 days |
| Vitamins, Minerals And Trace Elements With CarbohydratePaediatric Seravit® | Dietary management of conditions requiring a highly restrictive therapeutic diet | Jul 2020 | 2186 days |
| Carbohydrate, Fat, Vitamins, Minerals And Trace ElementsEnergivit® | Proven inborn errors of protein metabolism | Jul 2020 | 2186 days |
| Milk Powder Synthetic Low CalciumLocasol® | Hypercalcaemia | Jul 2020 | 2186 days |
| Fosnetupitant (As Chloride Hydrochloride)/Palonosetron (As Hydrochloride)AKYNZEO IV® | Nausea and vomiting | Jul 2020 | 2186 days |
| GuselkumabTremfya® | Severe chronic plaque psoriasis | Jul 2020 | 2186 days |
| Triglycerides Medium Chain FormulaMonogen® | Dietary management of conditions requiring a source of medium chain triglycerides, … | Jul 2020 | 2186 days |
| Whey Protein Formula Supplemented With Amino Acids, Vitamins And Minerals, And Low In Protein, Phosphate, Potassium And LactoseKindergen® | Chronic Renal Failure (CRF) | Jul 2020 | 2186 days |
| Amino Acid Formula With Vitamins, Minerals And Long Chain Polyunsaturated Fatty Acids Without Phenylalanine; Amino Acid Formula With Vitamins And Minerals Without Phenylalanine And Tyrosine; Amino Acid Formula With Vitamins And Minerals Without LysinAnamix Infant® Formulas | Phenylketonuria (PKU); Tyrosinaemia (TYR); Glutaric Aciduria Type 1; Methylmalonic … | Jul 2020 | 2186 days |
| FulvestrantFaslodex® | Breast cancer | Jul 2020 | 2186 days |
| EnoxaparinEnoxapo® | Prevention and treatment of deep vein thrombosis; haemodialysis | Jul 2020 | 2186 days |
| BimatoprostVizo-PF Bimatoprost® | Reduction of elevated intraocular pressure or open angle glaucoma, as first line therapy … | Jul 2020 | 2186 days |
| Fluocinolone AcetonideIluvien® | Diabetic macular oedema | Mar 2020 | 2305 days |
| Triglycerides Medium Chain FormulaLipistart® | Dietary management of conditions requiring a source of medium chain triglycerides | Mar 2020 | 2305 days |
| DupilumabDupixent® | Atopic dermatitis | Mar 2020 | 2305 days |
| Whey Protein Formula Supplemented With Amino Acids, Long Chain Polyunsaturated Fatty Acids, Vitamins And Minerals, Low In Protein, Phosphate, Potassium And LactoseRenastart® | Chronic kidney disease (CKD) | Mar 2020 | 2305 days |
| Milk Protein And Fat Formula With Vitamins And Minerals Carbohydrate FreeCarbohydrate Free Mix® | Ketogenic diet | Mar 2020 | 2305 days |
| Amino Acid Synthetic Formula Supplemented With Long Chain Polyunsaturated Fatty Acids Amino Acid Formula Supplemented With Prebiotics, Probiotics And Long Chain Polyunsaturated Fatty AcidsNeocate LCP® Neocate Syneo® | Cow’s milk allergy, multiple food intolerance and other medical conditions where an … | Mar 2020 | 2305 days |
| Triglycerides Medium Chain And Long Chain With Glucose PolymerDuocal® | Proven inborn errors of protein metabolism | Mar 2020 | 2305 days |
| Glycomacropeptide And Essential Amino Acids With Vitamins And MineralsPKU Build® 10; PKU Build® 20 | Phenylketonuria | Nov 2019 | 2431 days |
| Dimethyl FumarateTecfidera® | Relapsing-remitting multiple sclerosis (RRMS) | Nov 2019 | 2431 days |
| BrivaracetamBriviact® | Epilepsy | Nov 2019 | 2431 days |
| Amino Acid Formula With Vitamins With Minerals, Without Valine, Leucine And Isoleucine With Docosohexaenoic Acid And Arachidonic AcidMSUD explore® | Maple syrup urine disease | Nov 2019 | 2431 days |
| Tezacaftor With IvacaftorSymdeko® | Cystic Fibrosis (CF) | Nov 2019 | 2431 days |
| IbrutinibImbruvica® | Chronic lymphocytic leukaemia (CLL); small lymphocytic lymphoma (SLL) | Nov 2019 | 2431 days |
| Protein Formula With Vitamins And Minerals, And Low In Potassium, Phosphorus, Calcium, Chloride And Vitamin ARenastep® | Chronic kidney disease (CKD) | Nov 2019 | 2431 days |
| SemaglutideOzempic® | Type 2 diabetes mellitus (T2DM) | Nov 2019 | 2431 days |
| GalcanezumabEmgality® | Chronic migraine | Jul 2019 | 2550 days |
| Fluticasone FuroateArnuity Ellipta® | Asthma | Jul 2019 | 2550 days |
| Recommended Outcome For A Pbac Submission | — | days | |
| CemiplimabLibtayo® | Cervical cancer | — | days |
| Daunorubicin With CytarabineVyxeos® | Acute myeloid leukaemia | — | days |
| AfliberceptEydenzelt® | Branch retinal vein occlusion with macular oedema; Central retinal vein occlusion … | — | days |
| DupilumabDupixent® | Chronic severe atopic dermatitis | — | days |
| DelgocitinibAnzupgo® | Chronic hand eczema (CHE) | — | days |
| TeprotumumabTepezza® | Thyroid eye disease (TED) | — | days |
| GuselkumabTremfya® | Severe Crohn disease (CD) | — | days |
| Estradiol With ProgesteroneBijuva® | Vasomotor symptoms in post-menopausal women | — | days |
| AcalabrutinibCalquence® | Mantle cell lymphoma (MCL) | — | days |